These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27586591)

  • 1. Identification and functional characterization of the miRNA-gene regulatory network in chronic myeloid leukemia lineage negative cells.
    Agatheeswaran S; Pattnayak NC; Chakraborty S
    Sci Rep; 2016 Sep; 6():32493. PubMed ID: 27586591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
    Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
    Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
    Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY
    Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A.
    Kaymaz BT; Günel NS; Ceyhan M; Çetintaş VB; Özel B; Yandım MK; Kıpçak S; Aktan Ç; Gökbulut AA; Baran Y; Can BK
    Tumour Biol; 2015 Sep; 36(10):7915-27. PubMed ID: 25953263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance.
    Wu YY; Lai HF; Huang TC; Chen YG; Ye RH; Chang PY; Lai SW; Chen YC; Lee CH; Liu WN; Dai MS; Chen JH; Ho CL; Chiu YL
    Cell Death Dis; 2021 Oct; 12(10):908. PubMed ID: 34611140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
    Farhadi E; Zaker F; Safa M; Rezvani MR
    Tumour Biol; 2016 Oct; 37(10):14117-14128. PubMed ID: 27517565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.
    Kayabasi C; Okcanoglu TB; Yelken BO; Asik A; Susluer SY; Avci CB; Saydam G; Gunduz C
    Gene; 2017 Dec; 637():173-180. PubMed ID: 28942039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying and validating a combined mRNA and microRNA signature in response to imatinib treatment in a chronic myeloid leukemia cell line.
    Bhutra S; Lenkala D; LaCroix B; Ye M; Huang RS
    PLoS One; 2014; 9(12):e115003. PubMed ID: 25506832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
    Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G
    Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia.
    Wen F; Cao YX; Luo ZY; Liao P; Lu ZW
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):1-8. PubMed ID: 30366670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNAs that affect the Fanconi Anemia/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations.
    Yap E; Norziha ZA; Simbun A; Tumian NR; Cheong SK; Leong CF; Wong CL
    Leuk Res; 2017 Aug; 59():32-40. PubMed ID: 28544907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
    Li H; Liu L; Zhuang J; Liu C; Zhou C; Yang J; Gao C; Liu G; Sun C
    Mol Genet Genomic Med; 2019 Sep; 7(9):e851. PubMed ID: 31373443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI.
    Moreno-Lorenzana D; Avilés-Vazquez S; Sandoval Esquivel MA; Alvarado-Moreno A; Ortiz-Navarrete V; Torres-Martínez H; Ayala-Sánchez M; Mayani H; Chavez-Gonzalez A
    Cell Cycle; 2016 May; 15(9):1276-87. PubMed ID: 26985855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells.
    Chen PH; Liu AJ; Ho KH; Chiu YT; Anne Lin ZH; Lee YT; Shih CM; Chen KC
    Chem Biol Interact; 2018 Aug; 291():144-151. PubMed ID: 29890129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of miR-451 in Tunisian chronic myeloid leukemia patients: potential implication in imatinib resistance.
    Soltani I; Douzi K; Gharbi H; Benhassine I; Teber M; Amouri H; Ben Hadj Othman H; Farrah A; Ben Lakhel R; Abbes S; Menif S
    Hematology; 2017 May; 22(4):201-207. PubMed ID: 27825294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
    Xu C; Fu H; Gao L; Wang L; Wang W; Li J; Li Y; Dou L; Gao X; Luo X; Jing Y; Chim CS; Zheng X; Yu L
    Oncogene; 2014 Jan; 33(1):44-54. PubMed ID: 23208504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing of miR-21 sensitizes CML CD34+ stem/progenitor cells to imatinib-induced apoptosis by blocking PI3K/AKT pathway.
    Wang WZ; Pu QH; Lin XH; Liu MY; Wu LR; Wu QQ; Chen YH; Liao FF; Zhu JY; Jin XB
    Leuk Res; 2015 Oct; 39(10):1117-24. PubMed ID: 26248946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate.
    Martins JRB; Moraes LN; Cury SS; Capannacci J; Carvalho RF; Nogueira CR; Hokama NK; Hokama POM
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
    Joshi D; Chandrakala S; Korgaonkar S; Ghosh K; Vundinti BR
    Gene; 2014 Jun; 542(2):109-12. PubMed ID: 24680705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.